APO Research
Talk to an analyst

APO RESEARCH · REPORT

Diabetes Stem Cell Therapy

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Diabetes Stem Cell Therapy Market Outlook and Growth Opportunities 2026

29 December 2025195 pages

Choose your research edition.

Industry ResearchDiabetes Stem Cell Therapy Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal Diabetes Stem Cell Therapy Industry Growth and Trends Forecast to 203287 pages · $3,450 USDMarket StructureGlobal Diabetes Stem Cell Therapy Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032189 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Diabetes Stem Cell Therapy Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Diabetes Stem Cell Therapy Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Diabetes Stem Cell Therapy market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Diabetes Stem Cell Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Diabetes Stem Cell Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Diabetes Stem Cell Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Diabetes Stem Cell Therapy market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Diabetes Stem Cell Therapy market include CellTrans, CRISPR Therapeutics, iTolerance, Seraxi, Sernova, Vertex Pharmaceuticals and Eli Lilly, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Diabetes Stem Cell Therapy market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Diabetes Stem Cell Therapy and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Diabetes Stem Cell Therapy revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Diabetes Stem Cell Therapy market.

Diabetes Stem Cell Therapy Segment by Company

CellTrans

CRISPR Therapeutics

iTolerance

Seraxi

Sernova

Vertex Pharmaceuticals

Eli Lilly

Diabetes Stem Cell Therapy Segment by Type

Preclinical

Clinical Phase

Diabetes Stem Cell Therapy Segment by Application

Type 1 Diabetes

Type 2 Diabetes

Diabetes Stem Cell Therapy Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Diabetes Stem Cell Therapy status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Diabetes Stem Cell Therapy key companies, revenue, market share, and recent developments.

3. To split the Diabetes Stem Cell Therapy breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Diabetes Stem Cell Therapy market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Diabetes Stem Cell Therapy significant trends, drivers, influence factors in global and regions.

6. To analyze Diabetes Stem Cell Therapy competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Diabetes Stem Cell Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Diabetes Stem Cell Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Diabetes Stem Cell Therapy.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Diabetes Stem Cell Therapy industry.

Chapter 3: Detailed analysis of Diabetes Stem Cell Therapy company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Diabetes Stem Cell Therapy in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Diabetes Stem Cell Therapy in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Diabetes Stem Cell Therapy Industry Trends Table 2. Diabetes Stem Cell Therapy Industry Drivers Table 3. Diabetes Stem Cell Therapy Industry Opportunities and Challenges Table 4. Diabetes Stem Cell Therapy Industry Restraints Table 5. Global Diabetes Stem Cell Therapy Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Diabetes Stem Cell Therapy Revenue Share by Company (2021-2026) Table 7. Global Diabetes Stem Cell Therapy Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Diabetes Stem Cell Therapy Key Company Manufacturing Base & Headquarters Table 9. Global Diabetes Stem Cell Therapy Company, Product Type & Application Table 10. Global Diabetes Stem Cell Therapy Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Diabetes Stem Cell Therapy by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Preclinical Table 15. Significant Companies of Clinical Phase Table 16. Global Diabetes Stem Cell Therapy Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Diabetes Stem Cell Therapy Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Diabetes Stem Cell Therapy Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Diabetes Stem Cell Therapy Sales Value Share by Type (2021-2026) Table 20. Global Diabetes Stem Cell Therapy Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Type 1 Diabetes Table 22. Significant Companies of Type 2 Diabetes Table 23. Global Diabetes Stem Cell Therapy Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 24. Global Diabetes Stem Cell Therapy Sales Value by Application (2021-2026) & (US$ Million) Table 25. Global Diabetes Stem Cell Therapy Sales Value by Application (2027-2032) & (US$ Million) Table 26. Global Diabetes Stem Cell Therapy Sales Value Share by Application (2021-2026) Table 27. Global Diabetes Stem Cell Therapy Sales Value Share by Application (2027-2032) Table 28. Global Diabetes Stem Cell Therapy Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Diabetes Stem Cell Therapy Sales Value by Region (2021-2026) & (US$ Million) Table 30. Global Diabetes Stem Cell Therapy Sales Value Share by Region (2021-2026) Table 31. Global Diabetes Stem Cell Therapy Sales Value by Region (2027-2032) & (US$ Million) Table 32. Global Diabetes Stem Cell Therapy Sales Value Share by Region (2027-2032) Table 33. Global Diabetes Stem Cell Therapy Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Diabetes Stem Cell Therapy Sales Value by Country (2021-2026) & (US$ Million) Table 35. Global Diabetes Stem Cell Therapy Sales Value Market Share by Country (2021-2026) Table 36. Global Diabetes Stem Cell Therapy Sales Value by Country (2027-2032) & (US$ Million) Table 37. Global Diabetes Stem Cell Therapy Sales Value Market Share by Country (2027-2032) Table 38. CellTrans Company Information Table 39. CellTrans Business Overview Table 40. CellTrans Diabetes Stem Cell Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 41. CellTrans Diabetes Stem Cell Therapy Product Portfolio Table 42. CellTrans Recent Development Table 43. CRISPR Therapeutics Company Information Table 44. CRISPR Therapeutics Business Overview Table 45. CRISPR Therapeutics Diabetes Stem Cell Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 46. CRISPR Therapeutics Diabetes Stem Cell Therapy Product Portfolio Table 47. CRISPR Therapeutics Recent Development Table 48. iTolerance Company Information Table 49. iTolerance Business Overview Table 50. iTolerance Diabetes Stem Cell Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 51. iTolerance Diabetes Stem Cell Therapy Product Portfolio Table 52. iTolerance Recent Development Table 53. Seraxi Company Information Table 54. Seraxi Business Overview Table 55. Seraxi Diabetes Stem Cell Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 56. Seraxi Diabetes Stem Cell Therapy Product Portfolio Table 57. Seraxi Recent Development Table 58. Sernova Company Information Table 59. Sernova Business Overview Table 60. Sernova Diabetes Stem Cell Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 61. Sernova Diabetes Stem Cell Therapy Product Portfolio Table 62. Sernova Recent Development Table 63. Vertex Pharmaceuticals Company Information Table 64. Vertex Pharmaceuticals Business Overview Table 65. Vertex Pharmaceuticals Diabetes Stem Cell Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Vertex Pharmaceuticals Diabetes Stem Cell Therapy Product Portfolio Table 67. Vertex Pharmaceuticals Recent Development Table 68. Eli Lilly Company Information Table 69. Eli Lilly Business Overview Table 70. Eli Lilly Diabetes Stem Cell Therapy Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Eli Lilly Diabetes Stem Cell Therapy Product Portfolio Table 72. Eli Lilly Recent Development Table 73. Research Programs/Design for This Report Table 74. Authors List of This Report Table 75. Secondary Sources Table 76. Primary Sources List of Figures Figure 1. Diabetes Stem Cell Therapy Product Image Figure 2. Global Diabetes Stem Cell Therapy Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Diabetes Stem Cell Therapy Market Size (2021-2032) & (US$ Million) Figure 4. Global Diabetes Stem Cell Therapy Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Preclinical Image Figure 8. Clinical Phase Image Figure 9. Global Diabetes Stem Cell Therapy Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Diabetes Stem Cell Therapy Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Diabetes Stem Cell Therapy Sales Value Share by Type (2021-2032) Figure 12. Type 1 Diabetes Image Figure 13. Type 2 Diabetes Image Figure 14. Global Diabetes Stem Cell Therapy Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Diabetes Stem Cell Therapy Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Diabetes Stem Cell Therapy Sales Value Share by Application (2021-2032) Figure 17. Global Diabetes Stem Cell Therapy Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 18. Global Diabetes Stem Cell Therapy Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 19. North America Diabetes Stem Cell Therapy Sales Value (2021-2032) & (US$ Million) Figure 20. North America Diabetes Stem Cell Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 21. Europe Diabetes Stem Cell Therapy Sales Value (2021-2032) & (US$ Million) Figure 22. Europe Diabetes Stem Cell Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Asia-Pacific Diabetes Stem Cell Therapy Sales Value (2021-2032) & (US$ Million) Figure 24. Asia-Pacific Diabetes Stem Cell Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 25. South America Diabetes Stem Cell Therapy Sales Value (2021-2032) & (US$ Million) Figure 26. South America Diabetes Stem Cell Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Middle East & Africa Diabetes Stem Cell Therapy Sales Value (2021-2032) & (US$ Million) Figure 28. Middle East & Africa Diabetes Stem Cell Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 29. USA Diabetes Stem Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 30. USA Diabetes Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 31. USA Diabetes Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 32. Canada Diabetes Stem Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. Canada Diabetes Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. Canada Diabetes Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Mexico Diabetes Stem Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Mexico Diabetes Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Mexico Diabetes Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Germany Diabetes Stem Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Germany Diabetes Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Germany Diabetes Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. France Diabetes Stem Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. France Diabetes Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. France Diabetes Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. U.K. Diabetes Stem Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. U.K. Diabetes Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. U.K. Diabetes Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Italy Diabetes Stem Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Italy Diabetes Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Italy Diabetes Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Spain Diabetes Stem Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Spain Diabetes Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Spain Diabetes Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Russia Diabetes Stem Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Russia Diabetes Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Russia Diabetes Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Netherlands Diabetes Stem Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Netherlands Diabetes Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Netherlands Diabetes Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Nordic Countries Diabetes Stem Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Nordic Countries Diabetes Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Nordic Countries Diabetes Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. China Diabetes Stem Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. China Diabetes Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. China Diabetes Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Japan Diabetes Stem Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Japan Diabetes Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Japan Diabetes Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. South Korea Diabetes Stem Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. South Korea Diabetes Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. South Korea Diabetes Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. India Diabetes Stem Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. India Diabetes Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. India Diabetes Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Australia Diabetes Stem Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Australia Diabetes Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Australia Diabetes Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Southeast Asia Diabetes Stem Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Southeast Asia Diabetes Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Southeast Asia Diabetes Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Brazil Diabetes Stem Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Brazil Diabetes Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Brazil Diabetes Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Argentina Diabetes Stem Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Argentina Diabetes Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Argentina Diabetes Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Chile Diabetes Stem Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Chile Diabetes Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Chile Diabetes Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Colombia Diabetes Stem Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Colombia Diabetes Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Colombia Diabetes Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Peru Diabetes Stem Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Peru Diabetes Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Peru Diabetes Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Saudi Arabia Diabetes Stem Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Saudi Arabia Diabetes Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Diabetes Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Israel Diabetes Stem Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Israel Diabetes Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Israel Diabetes Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. UAE Diabetes Stem Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. UAE Diabetes Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. UAE Diabetes Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Turkey Diabetes Stem Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Turkey Diabetes Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Turkey Diabetes Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Iran Diabetes Stem Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Iran Diabetes Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Iran Diabetes Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Egypt Diabetes Stem Cell Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Egypt Diabetes Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Egypt Diabetes Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Years Considered Figure 114. Research Process Figure 115. Key Executives Interviewed

Scope & coverage.

Types
  • Preclinical
  • Clinical Phase
Applications
  • Type 1 Diabetes
  • Type 2 Diabetes
Companies covered
  • CellTrans
  • CRISPR Therapeutics
  • iTolerance
  • Seraxi
  • Sernova
  • Vertex Pharmaceuticals
  • Eli Lilly

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Diabetes Stem Cell Therapy Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Diabetes Stem Cell Therapy Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Diabetes Stem Cell Therapy Market Dynamics
  1. 2.1 Diabetes Stem Cell Therapy Industry Trends
  2. 2.2 Diabetes Stem Cell Therapy Industry Drivers
  3. 2.3 Diabetes Stem Cell Therapy Industry Opportunities and Challenges
  4. 2.4 Diabetes Stem Cell Therapy Industry Restraints
3 Diabetes Stem Cell Therapy Market by Company
  1. 3.1 Global Diabetes Stem Cell Therapy Company Revenue Ranking in 2025
  2. 3.2 Global Diabetes Stem Cell Therapy Revenue by Company (2021-2026)
  3. 3.3 Global Diabetes Stem Cell Therapy Company Ranking (2024-2026)
  4. 3.4 Global Diabetes Stem Cell Therapy Company Manufacturing Base and Headquarters
  5. 3.5 Global Diabetes Stem Cell Therapy Company Product Type and Application
  6. 3.6 Global Diabetes Stem Cell Therapy Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Diabetes Stem Cell Therapy Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Diabetes Stem Cell Therapy Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Diabetes Stem Cell Therapy Market by Type
  1. 4.1 Diabetes Stem Cell Therapy Type Introduction
  2. 4.1.1 Preclinical
  3. 4.1.2 Clinical Phase
  4. 4.2 Global Diabetes Stem Cell Therapy Sales Value by Type
  5. 4.2.1 Global Diabetes Stem Cell Therapy Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Diabetes Stem Cell Therapy Sales Value by Type (2021-2032)
  7. 4.2.3 Global Diabetes Stem Cell Therapy Sales Value Share by Type (2021-2032)
5 Diabetes Stem Cell Therapy Market by Application
  1. 5.1 Diabetes Stem Cell Therapy Application Introduction
  2. 5.1.1 Type 1 Diabetes
  3. 5.1.2 Type 2 Diabetes
  4. 5.2 Global Diabetes Stem Cell Therapy Sales Value by Application
  5. 5.2.1 Global Diabetes Stem Cell Therapy Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Diabetes Stem Cell Therapy Sales Value by Application (2021-2032)
  7. 5.2.3 Global Diabetes Stem Cell Therapy Sales Value Share by Application (2021-2032)
6 Diabetes Stem Cell Therapy Regional Value Analysis
  1. 6.1 Global Diabetes Stem Cell Therapy Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Diabetes Stem Cell Therapy Sales Value by Region (2021-2032)
  3. 6.2.1 Global Diabetes Stem Cell Therapy Sales Value by Region: 2021-2026
  4. 6.2.2 Global Diabetes Stem Cell Therapy Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Diabetes Stem Cell Therapy Sales Value (2021-2032)
  7. 6.3.2 North America Diabetes Stem Cell Therapy Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Diabetes Stem Cell Therapy Sales Value (2021-2032)
  10. 6.4.2 Europe Diabetes Stem Cell Therapy Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Diabetes Stem Cell Therapy Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Diabetes Stem Cell Therapy Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Diabetes Stem Cell Therapy Sales Value (2021-2032)
  16. 6.6.2 South America Diabetes Stem Cell Therapy Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Diabetes Stem Cell Therapy Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Diabetes Stem Cell Therapy Sales Value Share by Country, 2025 VS 2032
7 Diabetes Stem Cell Therapy Country-level Value Analysis
  1. 7.1 Global Diabetes Stem Cell Therapy Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Diabetes Stem Cell Therapy Sales Value by Country (2021-2032)
  3. 7.2.1 Global Diabetes Stem Cell Therapy Sales Value by Country (2021-2026)
  4. 7.2.2 Global Diabetes Stem Cell Therapy Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Diabetes Stem Cell Therapy Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Diabetes Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Diabetes Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Diabetes Stem Cell Therapy Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Diabetes Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Diabetes Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Diabetes Stem Cell Therapy Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Diabetes Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Diabetes Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Diabetes Stem Cell Therapy Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Diabetes Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Diabetes Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Diabetes Stem Cell Therapy Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Diabetes Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Diabetes Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Diabetes Stem Cell Therapy Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Diabetes Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Diabetes Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Diabetes Stem Cell Therapy Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Diabetes Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Diabetes Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Diabetes Stem Cell Therapy Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Diabetes Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Diabetes Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Diabetes Stem Cell Therapy Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Diabetes Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Diabetes Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Diabetes Stem Cell Therapy Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Diabetes Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Diabetes Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Diabetes Stem Cell Therapy Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Diabetes Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Diabetes Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Diabetes Stem Cell Therapy Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Diabetes Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Diabetes Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Diabetes Stem Cell Therapy Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Diabetes Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Diabetes Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Diabetes Stem Cell Therapy Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Diabetes Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Diabetes Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Diabetes Stem Cell Therapy Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Diabetes Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Diabetes Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Diabetes Stem Cell Therapy Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Diabetes Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Diabetes Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Diabetes Stem Cell Therapy Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Diabetes Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Diabetes Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Diabetes Stem Cell Therapy Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Diabetes Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Diabetes Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Diabetes Stem Cell Therapy Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Diabetes Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Diabetes Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Diabetes Stem Cell Therapy Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Diabetes Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Diabetes Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Diabetes Stem Cell Therapy Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Diabetes Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Diabetes Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Diabetes Stem Cell Therapy Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Diabetes Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Diabetes Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Diabetes Stem Cell Therapy Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Diabetes Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Diabetes Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Diabetes Stem Cell Therapy Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Diabetes Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Diabetes Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Diabetes Stem Cell Therapy Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Diabetes Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Diabetes Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Diabetes Stem Cell Therapy Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Diabetes Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Diabetes Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Diabetes Stem Cell Therapy Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Diabetes Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Diabetes Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Diabetes Stem Cell Therapy Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Diabetes Stem Cell Therapy Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Diabetes Stem Cell Therapy Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 CellTrans
  2. 8.1.1 CellTrans Company Information
  3. 8.1.2 CellTrans Business Overview
  4. 8.1.3 CellTrans Diabetes Stem Cell Therapy Revenue and Gross Margin (2021-2026)
  5. 8.1.4 CellTrans Diabetes Stem Cell Therapy Product Portfolio
  6. 8.1.5 CellTrans Recent Developments
  7. 8.2 CRISPR Therapeutics
  8. 8.2.1 CRISPR Therapeutics Company Information
  9. 8.2.2 CRISPR Therapeutics Business Overview
  10. 8.2.3 CRISPR Therapeutics Diabetes Stem Cell Therapy Revenue and Gross Margin (2021-2026)
  11. 8.2.4 CRISPR Therapeutics Diabetes Stem Cell Therapy Product Portfolio
  12. 8.2.5 CRISPR Therapeutics Recent Developments
  13. 8.3 iTolerance
  14. 8.3.1 iTolerance Company Information
  15. 8.3.2 iTolerance Business Overview
  16. 8.3.3 iTolerance Diabetes Stem Cell Therapy Revenue and Gross Margin (2021-2026)
  17. 8.3.4 iTolerance Diabetes Stem Cell Therapy Product Portfolio
  18. 8.3.5 iTolerance Recent Developments
  19. 8.4 Seraxi
  20. 8.4.1 Seraxi Company Information
  21. 8.4.2 Seraxi Business Overview
  22. 8.4.3 Seraxi Diabetes Stem Cell Therapy Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Seraxi Diabetes Stem Cell Therapy Product Portfolio
  24. 8.4.5 Seraxi Recent Developments
  25. 8.5 Sernova
  26. 8.5.1 Sernova Company Information
  27. 8.5.2 Sernova Business Overview
  28. 8.5.3 Sernova Diabetes Stem Cell Therapy Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Sernova Diabetes Stem Cell Therapy Product Portfolio
  30. 8.5.5 Sernova Recent Developments
  31. 8.6 Vertex Pharmaceuticals
  32. 8.6.1 Vertex Pharmaceuticals Company Information
  33. 8.6.2 Vertex Pharmaceuticals Business Overview
  34. 8.6.3 Vertex Pharmaceuticals Diabetes Stem Cell Therapy Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Vertex Pharmaceuticals Diabetes Stem Cell Therapy Product Portfolio
  36. 8.6.5 Vertex Pharmaceuticals Recent Developments
  37. 8.7 Eli Lilly
  38. 8.7.1 Eli Lilly Company Information
  39. 8.7.2 Eli Lilly Business Overview
  40. 8.7.3 Eli Lilly Diabetes Stem Cell Therapy Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Eli Lilly Diabetes Stem Cell Therapy Product Portfolio
  42. 8.7.5 Eli Lilly Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst